Archemix Company Description
Monoclonal antibodies and small molecules? Feh! Archemix is focused on aptamers, a type of synthetic oligonucleotide that the drug discovery company believes will trump those other cutting edge biotech tools in treating acute and chronic diseases. Aptamers bind to molecular targets much like antibodies but are more easily reproduced. The company's lead aptamer candidate is designed to inhibit blood clotting for use in the treatment of heart attacks and strokes. Another candidate is being evaluated for possible use in treating eye diseases and age-related macular degeneration. The company has partnered with larger firms including Merck Serono and OSI Pharmaceuticals.
View the Comprehensive Company Description for Archemix
The Company Description provides a historical perspective of Archemix's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Archemix's evolution in the marketplace.
